A. Trojan

Type de document

Articles (5)

Co-auteur

Date

Source

Mot-clé

Patients (5) Patients (5) maladie (4) survie (4) Treatment (4) Chemotherapy (4) Survival (4) Chemotherapy (4) maladie (4) thérapie (3) procès (3) cancer (3) taux (3) Cancer (3) Ci (Chinese poetry) (3) Therapeutics (3) Months (3) Human beings (3) Cancer (3) Breast (3) Older people (3) toxicité (2) temps (durée) (2) étable (2) protéine (2) analyse (2) adulte (2) Control (2) Methods (2) Paclitaxel (2)

Documents écrit par A. Trojan (5) | parle de A. Trojan (0)

Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].
U. Hasler-Strub et al.
Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients.
S. Cattin et al. (8 mars 2016)
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
C. Rochlitz et al. (2016)
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
C. Renner et al. (2012)
Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma.
A. Trojan et al. (24 juin 2006)